WNT974

DRUG2 trials

Sponsors

Array BioPharma, University of Michigan Rogel Cancer Center

Conditions

Metastatic Colorectal CancerSquamous Cell Carcinoma, Head And Neck

Phase 1

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

CompletedNCT02278133

Array BioPharmaMetastatic Colorectal Cancer

Start: 2014-12-31End: 2017-06-23Updated: 2017-10-09

Phase 2

A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma

WithdrawnNCT02649530

University of Michigan Rogel Cancer CenterSquamous Cell Carcinoma, Head And Neck

Updated: 2016-09-30

Related Papers

Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial.

2025-07-01

A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.

2024-11-014 citations

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E</i>-Mutant<i>KRAS</i>Wild-Type Metastatic Colorectal Cancer

The Oncologist2023-02-2246 citations